Skip to Content
Merck
CN
  • Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer.

Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer.

British journal of cancer (2013-03-02)
J C Wilson, L J Murray, C M Hughes, A Black, L A Anderson
ABSTRACT

Evidence for non-steroidal anti-inflammatory drugs (NSAIDs) preventing head and neck cancer (HNC) is inconclusive; however, there is some suggestion that aspirin may exert a protective effect. Using data from the United States National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined the association between aspirin and ibuprofen use and HNC. Regular aspirin use was associated with a significant 22% reduction in HNC risk. No association was observed with regular ibuprofen use. Aspirin may have potential as a chemopreventive agent for HNC, but further investigation is warranted.

MATERIALS
Product Number
Brand
Product Description

Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
Supelco
Ibuprofen
Sigma-Aldrich
Ibuprofen, meets USP testing specifications
Sigma-Aldrich
Ibuprofen, ≥98% (GC)
Supelco
Ibuprofen sodium salt, ≥98% (GC)
Supelco
Ibuprofen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
(S)-(+)-Ibuprofen, ReagentPlus®, 99%